试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-12
Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations
编号:NCT01685658登记状态:入组前撤回企业 / 申办者:Centre Hospitalier Universitaire de Nīmes
药物 / 成分:Intravenous ketoprofen、Intravenous paracetamol
登记的停止原因(原文):same study already published
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-11
DAS181 for STOP COVID-19
编号:NCT04354389登记状态:入组前撤回企业 / 申办者:Ansun Biopharma, Inc.
药物 / 成分:DAS181、Placebo、DAS181
登记的停止原因(原文):No COVID-19 in EU countries - Sponsor withdraw in regulatory stage
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-11
Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen
编号:NCT04502069登记状态:入组前撤回企业 / 申办者:RedHill Biopharma Limited
药物 / 成分:Opaganib
登记的停止原因(原文):To be replaced with a randomized placebo-controlled study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-07
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
编号:NCT04039477登记状态:入组前撤回企业 / 申办者:Kezar Life Sciences, Inc.
药物 / 成分:KZR-616
登记的停止原因(原文):Clinical trial activity slowdown due to COVID-19 pandemic, high screen fail rate, and lack of enrollment led to the decision to withdraw the MARINA study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-05
Study of Busulfan for Refractory Central Nervous System (CNS) Tumors
编号:NCT00836628登记状态:入组前撤回企业 / 申办者:Ann & Robert H Lurie Children's Hospital of Chicago
药物 / 成分:Busulfan
登记的停止原因(原文):slow accrual
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-05
Impedance Cardiography to Decrease the Risk of Preeclampsia
编号:NCT03245970登记状态:入组前撤回企业 / 申办者:University of Tennessee Medical Center
药物 / 成分:Labetalol Hydrocholoride 200 mg orally every 12 hours、Nifedipine 60 mg orally daily、Atenolol 25 mg daily
登记的停止原因(原文):Investigator retired. Other investigators did not want to continue study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-04
NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study
编号:NCT02692157登记状态:入组前撤回企业 / 申办者:New York State Psychiatric Institute
药物 / 成分:Placebo、NT-814 50 mg、NT-814 100 mg、NT-814 200 mg
登记的停止原因(原文):The study was discontinued by the sponsor. No results to report
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-04
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
编号:NCT04260360登记状态:入组前撤回企业 / 申办者:NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)
药物 / 成分:NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
登记的停止原因(原文):Not initiated
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-04
Melatonin on Clock Genes in Parkinson's Disease
编号:NCT04287543登记状态:入组前撤回企业 / 申办者:Instituto Mexicano del Seguro Social
药物 / 成分:Melatonin、Placebos
登记的停止原因(原文):Due to the COVID-19 pandemic, we were unable to begin the study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-04
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
编号:NCT04353505登记状态:入组前撤回企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:Ketorolac、Dexamethasone
登记的停止原因(原文):PI closed the study before any enrollment
查看官方原始记录 ↗